Stocks · News reference
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
JP Morgan analyst Detlef Winckelmann upgrades Graphic Packaging Holding (NYSE:GPK) from Neutral to Overweight and lowers the price target from $12.5 to $11.5.
U.S. stocks fell Wednesday, led by a 1.1% Nasdaq drop. Cintas beat estimates and raised guidance; oil gained while gold, silver and copper declined.
RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.
Alebex AI, a Vancouver-based company, has achieved 8th place in Artificial Analysis's international speech-to-text accuracy benchmark, outperforming models from Google, Microsoft, Nvidia, and Amazon. This marks the first Canadian company in this category on the leaderboard and represents a significant step toward Canadian AI sovereignty and voice infrastructure development.